Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8039708 | 1.00 | PTPN1 (0.40) | PTPN1MAOBSTAT3PTGESALOX5 | |
| SCHEMBL8038304 | 1.00 | PTPN1 (0.40) | PTPN1MAOBSTAT3PTGESALOX5 | |
| SCHEMBL8039546 | 1.00 | PTPN1 (0.40) | PTPN1MAOBSTAT3PTGESALOX5 | |
| SCHEMBL8039689 | 0.99 | PTPN1 (0.38) | PTPN1MAOBSTAT3PTGESALOX5 | |
| SCHEMBL8041172 | 0.90 | TSPO (0.40) | PTPN1MAOBSTAT3ABCC1 | |
| SCHEMBL6406664 | 0.89 | TSPO (0.39) | ALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL8037926 | 0.89 | TSPO (0.39) | ALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL8038293 | 0.89 | TSPO (0.39) | ALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL8037891 | 0.88 | TSPO (0.40) | ALDH1A1LMNAPARP10KMT2ATSHR | |
| SCHEMBL8027781 | 0.86 | ABCC1 (0.40) | MAOBSTAT3PTGESALOX5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0806412-B1 | BENZENE DERIVATIVES | TEIJIN LTD (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-5808144-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0806412-A1 | BENZENE DERIVATIVES | TEIJIN LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | PTPN1 504/4885MAOB 1744/4885STAT3 1199/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | PTPN1 710/4885MAOB 1070/4885STAT3 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.